As the activation and overexpression of HSP90 in various cancers including lung cancer, breast cancer, and colorectal cancer, researchers have aimed to target HSP90 to interfere with the interaction with client proteins., This disruption results in the irreversible degradation of client proteins by the proteasome or lysosome pathway.23, 146, 147. This evidence concerns the gene HSP90AA1 and colorectal cancer.